Immodulon Therapeutics Ltd.

Immodulon is a private, late-stage clinical company developing IMM-101, a novel broad spectrum immunomodulator. Immodulon has generated promising phase II data with IMM-101 in first line patients with advanced pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine. Immodulon is planning to advance IMM-101 in a pivotal study in metastatic PDAC (mPDAC) patients. Immodulon is led by a new, highly experienced and successful management team, who have previously held senior global roles at companies including Celgene, Amgen and ADC Therapeutics. Immodulon is led by a new, highly experienced, and successful management team, who have previously held senior global roles at companies including Celgene, Amgen and ADC Therapeutics. Gertjan is a global biotech leader with over 25 years’ industry experience in finance, business development and operations. Peter is a highly experienced business development executive, with over 20 years’ international industry expertise. Josefine brings significant experience in drug development and medical affairs to Immodulon having held senior leadership roles at leading pharmaceutical companies including Celgene, Amgen and Ipsen.